Browse Studies — Arctuva

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia

The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in parti…

Severe Hypertriglyceridemia

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07269210

Phase 3

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of a…

Severe Hypertriglyceridemia

Estimated

~$10 – $8,750

Arrowhead PharmaceuticalsNCT06880770

Phase 1

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are ref…

CardiovascularMetabolic DiseaseDyslipidemias+7 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT07491172

Phase 2

A Phase 2, Open-label Trial Evaluating the Safety, Tolerability and Efficacy of ION775 in Adults With Hypertriglyceridemia

The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and se…

HypertriglyceridemiaSevere Hypertriglyceridemia

Estimated

~$10 – $8,750

Ionis Pharmaceuticals, Inc.NCT07604974